Maridebart Cafraglutide
NCT05669599
Amgen · Phase 2 · Completed · Enrollment 592
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort A: Maridebart Cafraglutide | n/r | n/r | n/r | n/r | n/r |
| Cohort A: Placebo | n/r | n/r | n/r | n/r | n/r |
| Cohort B: Maridebart Cafraglutide | n/r | n/r | n/r | n/r | n/r |
| Cohort B: Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.